Mahkam Zanganeh, Co-Chief Executive Officer and a director and 10% owner of Summit Therapeutics Inc. (NASDAQ:SMMT), filed a Form 4 on November 20, 2026, reporting the exercise of a stock option covering 300,000 shares of common stock.

Key Highlights

  • Option exercised: Zanganeh exercised an option to purchase 300,000 shares of Summit Therapeutics common stock on November 20, 2026, at an exercise price of $1.06 per share.
  • Direct ownership after transaction: Following the exercise, Zanganeh directly holds 831,000 shares of common stock.
  • Original grant date: The exercised option was originally granted on June 28, 2022, subject to certain performance criteria, with an expiration date of June 28, 2032.
  • Remaining options: After the exercise of 300,000 shares, Zanganeh holds 500,000 derivative securities (stock options with a right to buy) beneficially owned directly.
  • Indirect holdings: The filing reports indirect beneficial ownership of approximately 573,883,879 shares by spouse, 25,824,474 shares through the Mahkam Zanganeh Revocable Trust, 10,199,776 shares through the Shaun Zanganeh Irrevocable Trust, and 76,680 shares held by an immediate family member, all of which Zanganeh disclaims beneficial ownership of except to the extent of her pecuniary interest.

Zanganeh Option Exercise and Beneficial Ownership at Summit Therapeutics

According to the filing, Mahkam Zanganeh, serving as Co-Chief Executive Officer, Director, and 10% Owner of Summit Therapeutics Inc., exercised a stock option on November 20, 2026, acquiring 300,000 shares of common stock at $1.06 per share using transaction code "M," indicating an exercise of an in-the-money or at-the-money derivative security. The price of the derivative security at exercise was reported as $0. Following this transaction, Zanganeh's direct beneficial ownership stands at 831,000 shares.

The filing provides additional history on the exercised option. According to the filing, the option was granted on June 28, 2022, and was originally subject to certain performance criteria. The filing states that on August 23, 2024, the option vested as to 260,000 shares upon satisfaction of certain performance criteria. On April 29, 2025, the filing reports, the option was modified so that only service-based vesting requirements needed to be satisfied going forward; on that same date, the option vested as to 520,000 shares, with the remaining 520,000 shares to vest in three equal annual installments, the first of which occurred on October 13, 2025. The option carries an expiration date of June 28, 2032.

In addition to her direct holdings, the filing reports indirect beneficial ownership across several entities and individuals: 573,883,879 shares held by her spouse, 25,824,474 shares through the Mahkam Zanganeh Revocable Trust with Zanganeh as trustee, 10,199,776 shares through the Shaun Zanganeh Irrevocable Trust with Zanganeh as trustee, and 76,680 shares attributed to an immediate family member. The filing notes that Zanganeh "disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein."

What Was Disclosed

Summit Therapeutics Co-CEO Mahkam Zanganeh reported a November 20, 2026, exercise of a stock option for 300,000 shares at $1.06 per share, resulting in direct ownership of 831,000 shares, with 500,000 options remaining and significant indirect holdings also reported.